Harold M. Frost, M.D.; Boy Frame, M.D., F.A.C.P.; James R. Ramcer, M.D.; A. R. Arnstein, M.D.; Richmond W. Smith Jr., M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
A group of patients being studied for known or potential metabolic bone disease was given a double tetracycline label with 900 mg oral Dimethychloral tetracycline. An eleventh rib biopsy was then done under local anesthesia. With the aid of undecalcified sections and fluorescence microscopy, the bone turnover was measured and expressed as the per cent of the bone tissue being replaced by new tissue per year. In addition, indexes of the number of new osteoblasts generated by progenitor cells, and of the vigor of the representative individual osteoblast and osteoclast were measured.
We found that tissue turnover rates averaged below
Frost HM, Frame B, Ramcer JR, Arnstein AR, Smith RW. Measurement of Bone Tissue Turnover and Cell Dynamics in Metabolic Bone Disease by Means of In Vivo Tetracycline Bone Labeling.. Ann Intern Med. ;64:1172. doi: 10.7326/0003-4819-64-5-1172_2
Download citation file:
Published: Ann Intern Med. 1966;64(5):1172.
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use